FIGURE 4.

rTSMS treatment modulates glial and fibrotic scars but not primary bOEC transplantation. Representative pictures of sagittal spinal cord sections 60 days after SCI (a, b, c, d, f, g, h, and I 50× magnification) and border of the spinal cord scar (a', b', c', d', f', g', h', and i 200× magnification). (a and f) SCI control, (b and g) SCI + primary bOECs, (c and h) SCI + STM, (d and i) SCI + primary bOECs + STM. Sections were stained with (a–d) anti‐GFAP antibody, (f–j) anti‐PDGFrβ antibody and DAPI. Dotted lines show (a–d) astrocytic negative area (GFAP‐) and (f–i) PDGFrβ positive area (PDGFrβ+). (e and j) Quantitative analysis of (e) GFAP‐ areas and (j) PDGFrβ + areas. Quantifications are expressed as average ± standard deviation. N = 5 per group. Statistical evaluations were based on Kruskal–Wallis test (*p < 0.05; **p < 0.01)